慢性粒单核细胞白血病髓外病变:生物学、模式与管理
本文综述慢性粒单核细胞白血病(CMML)髓外病变(EMD)的流行病学、生物学、诊断、预后和治疗。EMD指克隆性髓单核细胞浸润骨髓外,约10-15%患者经活检证实为非肝脾EMD,多见于皮肤、淋巴结、浆液腔和软组织。EMD富集于增殖型和高危CMML,与总生存缩短和AML转化增加相关。管理以系统性治疗为主,低甲基化药物为骨架,局部放疗用于症状性病灶,高危或难治患者早期考虑异基因移植。
要点
- EMD指克隆性髓单核细胞浸润骨髓外,可主导临床表现并提示不良生物学。
- 活检证实的非肝脾EMD约占10-15%,多累及皮肤、淋巴结、浆液腔和软组织。
- EMD富集于增殖型和高危CMML,与总生存缩短和AML转化增加相关。
核心结论
- EMD是CMML中未被充分认识且具有临床后果的表现,与不良结局相关,需标准化定义和前瞻性基因组研究。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 肝脾受累常见,常反映髓外造血;活检证实的非肝脾EMD发生于10-15%患者,最常累及皮肤、淋巴结、浆液腔和软组织,内脏部位包括肺、肾和中枢神经系统。
- EMD富集于增殖型和高危CMML,与较短总生存和AML转化增加相关,EMD发生后预后差。
- EMD生物学上与突变驱动的增殖信号、RAS-MAPK通路改变富集、ASXL1等不良表观遗传病变共存、细胞因子介导的炎症及失调的 trafficking 和滞留程序相关。
关键数值与推荐
- 活检证实的非肝脾EMD发生于10-15%的患者。
- 诊断需整合横断面成像、PET-CT定位并优先活检靶点,以及组织确认和免疫表型(包括CD68、CD163和溶菌酶)及选择性分子分析以确定克隆性。
- 管理以系统性治疗为主,低甲基化药物为骨架,增殖性疾病行细胞减灭,症状性病灶行局部放疗,适合的高危或难治病例早期考虑异基因移植。
临床怎么用
- 对CMML患者出现皮肤、淋巴结、浆液腔或软组织等髓外表现时,应整合影像学和PET-CT定位活检,行免疫表型及分子分析确认克隆性。
- 治疗以低甲基化药物为骨架,结合细胞减灭、局部放疗,高危或难治患者早期评估异基因移植。
局限性
- 摘要未报告综述的检索范围、纳入研究数量及偏倚评估方法。
- EMD定义尚未标准化,缺乏前瞻性基因组研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myelomonocytic leukemia (CMML) is an MDS/MPN overlap neoplasm defined by monocytosis, clonal hematopoiesis, and marrow dysplasia, with outcomes ranging from indolent cytopenic disease to aggressive proliferative phenotypes with early AML transformation. Extramedullary disease (EMD) refers to clonal myelomonocytic infiltration outside the bone marrow and is an underrecognized, consequential manifestation that can dominate presentation, drive morbidity, and identify adverse disease biology. While hepatosplenic involvement, often reflecting extramedullary hematopoiesis, is common, biopsy proven non-hepatosplenic EMD occurs in a subset of patients, 10-15 percent, and most frequently involves skin, lymph nodes, serosal fluids, and soft tissue, with visceral sites including lung, kidney, and central nervous system. Importantly, EMD is enriched in proliferative and higher grade CMML and is associated with inferior outcomes, including shorter overall survival and increased AML transformation, with poor prognosis after EMD onset. Biologically, EMD appears linked to mutation-driven proliferative signaling, enrichment of RAS MAPK pathway alterations, co-occurring with adverse epigenetic lesions such as ASXL1, together with cytokine-mediated inflammation and dysregulated trafficking and retention programs that facilitate tissue homing and persistence. Because EMD frequently mimics infection, autoimmune and inflammatory syndromes common in CMML, or second malignancy, diagnosis requires an integrated strategy incorporating cross sectional imaging, PET-CT to localize and prioritize biopsy targets, and tissue confirmation with immunophenotyping including CD68, CD163, and lysozyme and selective molecular profiling to establish clonality. Management is primarily systemic, with hypomethylating agents as the backbone, cytoreduction for proliferative disease, local radiotherapy for symptomatic lesions, and early consideration of allogeneic transplantation in eligible high risk or refractory cases. This review synthesizes current evidence on the epidemiology, biology, diagnostic approach, prognostic implications, and treatment of EMD in CMML and highlights the need for standardized definitions and prospective, genomics-informed studies to improve detection and outcomes.
引用
- Ahmidouch M, Deshpande P, Salib C, et al. Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease. Leukemia. 2026. PMID: 42045559. doi:10.1038/s41375-026-02966-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。